Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in adolescent chronic spontaneous urticaria
NCT03437278Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of ligelizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Aug 2018; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03437278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437278.